Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

At the J.P. Morgan Healthcare Conference, Moderna (MRNA) announced several financial updates on its business and updates on its pipeline progress.Moderna’s Financial Updates Fail to Impress InvestorsFor 2024Moderna reported unaudited/preliminary product sales between $3 billion and $3.1 billion for 2024. This includes more than $3 billion in COVID-19 vaccine sales and minimal sales from the RSV vaccine mResvia. This figure was mainly toward the lower end of the company’s previously issued guidance of $3.0-$ ...